Name: Hassan Yousefi
Year in Program: 4th
Department: Biochemistry and Molecular Biology
Mentor: Dr. Suresh Alahari
Hometown: New Orleans
Education: MSc in Human Genetics
Past Research Experience: Master’s in human Genetics from Tehran University of Medical Sciences, Tehran, Iran
Current Research Interest: Breast cancer drug resistance and metastasis
Career Goal: Keep doing cancer research as a postdoctoral researcher
Publications:
Yousefi, H., Delavar, M. R., Piroozian, F., Baghi, M., Nguyen, K., Cheng, T., Vittori, C., Worthylake, D., and Alahari, S. K. (2022) Hippo signaling pathway: A comprehensive gene expression profile analysis in breast cancer. Biomedicine & pharmacotherapy, 151, 113144
Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel Okpechi, Margarite Matossian, Bridgette Collins-Burow, Mathew Burow, Suresh Alahari (2022) Ceritinib is a novel triple negative breast cancer therapeutic agent.
Co-first author, Molecular Cancer, accepted for publication
Vittori, C., Jeansonne, D., Yousefi, H., Faia, C., Lin, Z., Reiss, K., and Peruzzi, F. (2022) Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer. Cancer Cell International 22, 204
Yousefi, H., Fong, J., and Alahari, S. (2022) NR4A Family Genes: A Review of Comprehensive Prognostic and Gene Expression Profile Analysis in Breast Cancer. Front. Oncol 12, 777824
Nguyen, K., Yousefi, H., Cheng, T., Magrath, J., Hartono, A. B., Alzoubi, M., Hebert, K., Brock, C. K., Wright, M. K., and Byrne, C. E. (2022) Expression of Novel Kinase MAP3K19 in Various Cancers and Survival Correlations. Frontiers in Bioscience-Landmark 27, 196
Co-first author
Nasrollahzadeh, A., Momeny, M., Bashash, D., Yousefi, H., Mousavi, S. A., and Ghaffari, S. H. (2022) Blockade of Nuclear Factor-Κb (NF-Κb) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells. Reports of Biochemistry & Molecular Biology 10, 602
Okpechi, S. C., Yousefi, H., Nguyen, K., Cheng, T., Alahari, N. V., Collins-Burow, B., Burow, M. E., and Alahari, S. K. (2022) Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer. Oncogene, 1-8
Co-first author
Hosseini, R., Sarvnaz, H., Arabpour, M., Ramshe, S. M., Asef-Kabiri, L., Yousefi, H., Akbari, M. E., and Eskandari, N. (2022) Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy. Molecular Cancer 21, 1-18
Momeny, M., Shamsaiegahkani, S., Kashani, B., Hamzehlou, S., Esmaeili, F., Yousefi, H., Irani, S., Mousavi, S. A., and Ghaffari, S. H. (2021) Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells. Life Sciences 287, 120100
Hosseini, R., Asef-Kabiri, L., Yousefi, H., Sarvnaz, H., Salehi, M., Akbari, M. E., and Eskandari, N. (2021) The roles of tumor-derived exosomes in altered differentiation, maturation, and function of dendritic cells. Molecular Cancer 20, 1-17
Mohajan, S., Jaiswal, P. K., Vatanmakarian, M., Yousefi, H., Sankaralingam, S., Alahari, S. K., Koul, S., and Koul, H. K. (2021) Hippo pathway: Regulation, deregulation, and potential therapeutic targets in cancer. Cancer Letters 507, 112-123
Nguyen, K., Rivera, A., Alzoubi, M., Wathieu, H., Dong, S., Yousefi, H., Matossian, M., Alahari, S., Drewry, D., and Burow, M. (2021) Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment. Oncotarget 12, 1110
Kazemi, M. H., Najafi, A., Karami, J., Ghazizadeh, F., Yousefi, H., Falak, R., and Safari, E. (2021) Immune and metabolic checkpoints blockade: Dual wielding against tumors. International Immunopharmacology 94, 107461
Bitaraf, A., Razmara, E., Bakhshinejad, B., Yousefi, H., Vatanmakanian, M., Garshasbi, M., Cho, W. C., and Babashah, S. (2021) The oncogenic and tumor suppressive roles of RNA‐binding proteins in human cancers. Journal of Cellular Physiology
Yousefi, H., Vatanmakanian, M., Mahdiannasser, M., Mashouri, L., Alahari, N. V., Monjezi, M. R., Ilbeigi, S., and Alahari, S. K. (2021) Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance. Oncogene 40, 1043-1063
Lavasani, A., Hussen, B. M., Taheri, F., Sattari, A., Yousefi, H., Omrani, M. D., Nazer, N., Ghafouri-Fard, S., and Taheri, M. (2021) Opposite trends of GAS6 and GAS6-AS expressions in breast cancer tissues. Experimental and Molecular Pathology 118, 104600
Razmara, E., Salehi, M., Aslani, S., Bitaraf, A., Yousefi, H., Colón, J. R., and Mahmoudi, M. (2021) Graves’ disease: introducing new genetic and epigenetic contributors. Journal of Molecular Endocrinology 66, R33-R55
Ghaffari-Makhmalbaf, P., Sayyad, M., Pakravan, K., Razmara, E., Bitaraf, A., Bakhshinejad, B., Goudarzi, P., Yousefi, H., Pournaghshband, M., and Nemati, F. (2021) Docosahexaenoic acid reverses the promoting effects of breast tumor cell-derived exosomes on endothelial cell migration and angiogenesis. Life Sciences 264, 118719
Haghi, A., Salemi, M., Fakhimahmadi, A., Mohammadi Kian, M., Yousefi, H., Rahmati, M., Mohammadi, S., Ghavamzadeh, A., Moosavi, M. A., and Nikbakht, M. (2021) Effects of different autophagy inhibitors on sensitizing KG‐1 and HL‐60 leukemia cells to chemotherapy. IUBMB life 73, 130-145
Poursheikhani, A., Bahmanpour, Z., Razmara, E., Mashouri, L., Taheri, M., Morshedi Rad, D., Yousefi, H., Bitaraf, A., and Babashah, S. (2020) Non-coding RNAs underlying chemoresistance in gastric cancer. Cellular Oncology 43, 961-988
Bagheri-Hosseinabadi, Z., Imani, D., Yousefi, H., and Abbasifard, M. (2020) Vitamin D receptor (VDR) gene polymorphism and risk of rheumatoid arthritis (RA): systematic review and meta-analysis. Clinical Rheumatology 39, 3555-3569
Poursheikhani, A., Nokhandani, N., Yousefi, H., Rad, D. M., and Sahebkar, A. (2020) Clinicopathological significance of long non-coding RNA GHET1 in human cancers: a meta-analysis. Current Pharmaceutical Biotechnology 21, 1422-1432
Poursheikhani, A., Yousefi, H., Tavakoli-Bazzaz, J., and Ghaffari, S. H. (2020) EGFR blockade reverses cisplatin resistance in human epithelial ovarian cancer cells. Iranian Biomedical Journal 24, 370
Yousefi, H., Poursheikhani, A., Bahmanpour, Z., Vatanmakanian, M., Taheri, M., Mashouri, L., and Alahari, S. K. (2020) SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach. Biomedicine & Pharmacotherapy 130, 110548
Afrough, H., Ghafouri-Fard, S., Yousefi, H., Pakzad, P., Oskooei, V. K., and Taheri, M. (2020) DICER-AS1 lncRNA: A putative culprit in the pathogenesis of gastric cancer. Experimental and Molecular Pathology 116, 104490
Momeny, M., Sankanian, G., Hamzehlou, S., Yousefi, H., Esmaeili, F., Alishahi, Z., Karimi, B., Zandi, Z., Shamsaiegahkani, S., and Sabourinejad, Z. (2020) Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells. European Journal of Pharmacology 882, 173298
Bagheri-Hosseinabadi, Z., Imani, D., Yousefi, H., and Abbasifard, M. (2020) MTHFR gene polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis based on 16 studies. Clinical rheumatology 39, 2267-2279
Yousefi, H., Maheronnaghsh, M., Molaei, F., Mashouri, L., Aref, A. R., Momeny, M., and Alahari, S. K. (2020) Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene 39, 953-974
Noroozi, R., Sadeghi, E., Yousefi, H., Taheri, M., Sarabi, P., Dowati, A., Ayatallahi, S. A., Noroozi, R., and Ghafouri-Fard, S. (2019) Wound healing features of Prosopis farcta: in vitro evaluation of antibacterial, antioxidant, proliferative and angiogenic properties. Gene Reports 17, 100482
Mashouri, L., Yousefi, H., Aref, A. R., Molaei, F., and Alahari, S. K. (2019) Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Molecular cancer 18, 1-14
Co-first author
Hamzehlou, S., Momeny, M., Zandi, Z., Kashani, B., Yousefi, H., Dehpour, A. R., Tavakkoly-Bazzaz, J., and Ghaffari, S. H. (2019) Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells. European journal of pharmacology 863, 172705
Vatanmakanian, M., Yousefi, H., Mashouri, L., Aref, A. R., Khamisipour, G., Bitaraf, A., and Alizadeh, S. (2019) Generation of Induced Pluripotent Cancer Cells from Glioblastoma Multiform Cell Lines. Cellular reprogramming 21, 238-248
Momeny, M., Esmaeili, F., Hamzehlou, S., Yousefi, H., Javadikooshesh, S., Vahdatirad, V., Alishahi, Z., Mousavipak, S. H., Bashash, D., and Dehpour, A. R. (2019) The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cellular Oncology 42, 491-504
Yousefi, H., Momeny, M., Ghaffari, S. H., Parsanejad, N., Poursheikhani, A., Javadikooshesh, S., Zarrinrad, G., Esmaeili, F., Alishahi, Z., and Sabourinejad, Z. (2019) IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. Tumori journal 105, 84-91
Razmara, E., Bitaraf, A., Yousefi, H., Nguyen, T. H., Garshasbi, M., Cho, W. C.-s., and Babashah, S. (2019) Non-coding RNAs in cartilage development: an updated review. International journal of molecular sciences 20, 4475
Momeny, M., Yousefi, H., Eyvani, H., Moghaddaskho, F., Salehi, A., Esmaeili, F., Alishahi, Z., Barghi, F., Vaezijoze, S., and Shamsaiegahkani, S. (2018) Blockade of nuclear factor-κB (NF-κB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. The international journal of biochemistry & cell biology 99, 1-9
Co-first author
Shahsavani, N., Sheikhha, M. H., Yousefi, H., and Sefid, F. (2018) In silico homology modeling and epitope prediction of NadA as a potential vaccine candidate in Neisseria meningitidis. International journal of molecular and cellular medicine 7, 53
Esmaeili, F., Momeny, M., Yousefi, H., Eyvani, H., Sabourinejad, Z., Barghi, F., Vaezijoze, S., Alishahi, Z., Zarrinrad, G., and Poursheikhani, A. (2017) Dacomitinib, a pan-ErbB inhibitor, inhibits proliferation and invasion of pancreatic ductal adenocarcinoma cells. Annals of Oncology 28, x68-x69
Momeny, M., Zarrinrad, G., Moghaddaskho, F., Poursheikhani, A., Sankanian, G., Zaghal, A., Mirshahvaladi, S., Esmaeili, F., Eyvani, H., Barghi, F., Sabourinejad, Z., Alishahi, Z., Yousefi, H., Ghasemi, R., Dardaei, L., Bashash, D., Chahardouli, B., Dehpour, A. R., Tavakkoly-Bazzaz, J., Alimoghaddam, K., Ghavamzadeh, A., and Ghaffari, S. H. (2017) Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Scientific Reports 7, 4204
Momeny, M., Sabourinejad, Z., Zarrinrad, G., Moghaddaskho, F., Eyvani, H., Yousefi, H., Mirshahvaladi, S., Poursani, E. M., Barghi, F., and Poursheikhani, A. (2017) Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Scientific reports 7, 1-13
Momeny, M., Moghaddaskho, F., Gortany, N. K., Yousefi, H., Sabourinejad, Z., Zarrinrad, G., Mirshahvaladi, S., Eyvani, H., Barghi, F., and Ahmadinia, L. (2017) Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Scientific reports 7, 1-12